Dendreon will present Provenge data at the European Cancer Congress, shares up on premarket. Results from two studies show a "robust immune response when Provenge is administered with abiraterone acetate [and] suggest long-lived immunological memory to Provenge years following initial treatment.", reports Seeking Alpha. Dendreon is a very beaten down stock this year, it plummeted more than 100%, so good news can provoke significant bounce